 The objective of this study was to determine the effects of Imrecoxib, an anti-infiammatoryanalgesic agent that primarily inhibits COX-2 and not COX-1 at therapeutic doses, on the steady-state pharmacokinetic profile and hypoprothrombinemic effect of warfarin in healthy volunteers. 